Beyond the Pharma 50: Key Data Trends and Highlights

In this special slideshow presentation, explore a selection of graphical snapshots—a metrics mashup, if you will—spotlighting a handful of the pivotal, underlying, and overpowering (think GLP-1s) drivers of Pharm Exec's yearly Pharma 50 company rankings.

Featured ahead is drilled-down data on the latest trends around pipeline costs and market return (including first-time product launchers); biotech funding; the GLP-1 Rx curve; and a glimpse into today's active oncology R&D landscape, including exclusive, quick-hit insights on six perhaps under-the-radar players in our Top 50 that are advancing efforts in the cancer space.